Matthew Cooper, Ph.D., DABT, MBA, is currently the CEO and co-founder of Carmenta Bioscience, a company addressing unmet medical needs in maternal and fetal health. He also serves on the board of directors for the Preeclampsia Foundation, a patient advocacy group with the mission to reduce maternal and infant illness and death due to preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
Matthew has over 15 years experience in biomarker and drug development across the value chain. Past areas of specialty have included biomarker discovery and development, informatics, safety (toxicology and DMPK), and organizational/corporate strategy. Matthew has also served in leadership roles in miscellaneous industry consortia, including the Advisory Committee and Chair of the Data Analysis and Management Working Group for the Predictive Safety Testing Consortium (PSTC) at the Critical Path Institute.
Matthew's educational back ground is as diverse as his professional experience. He has recently added dual MBAs from Columbia Business School and the Berkeley Haas School of Business to his Ph.D. in Toxicology (University of Kentucky, College of Medicine) and B.S. in Chemistry (University of Tulsa, College of Engineering). He is board certified in toxicology (Diplomat of the American Board of Toxicology) and has earned a Certificate of Entrepreneurship from the Berkeley Haas School of Business.
Matthew advises several start-ups in the healthcare and healthcare IT spaces and is currently a mentor for the Business Association of Stanford Entrepreneurial Students, Berkeley Haas School of Business, and UCSF Lean LaunchPad for the Life Sciences. He is also a partner at Rudius, a premium, boutique winery located in Napa Valley.
CEO and Co-founder
Feb 1, 2012 - Current (over 4 years)
Board & Advisor Roles (2)Update
|Oct 29, 2015||Daily Mail - Boss of Aviva describes motor insurance fraud as ‘national scandal’ as former employee awaits sentencing for selling personal details of customers|
|Apr 29, 2015||Business Wire - Progenity Acquires Carmenta Bioscience for Proprietary Preeclampsia Technology; Appoints Matthew Cooper Chief Scientific Officer|
|Apr 29, 2015||Xconomy - Preeclampsia Test Developer Carmenta Bought For Undisclosed Sum|
|Apr 29, 2015||SoCal - Tech - Progenity Buys Carmenta Bioscience|
|Sep 10, 2014||TechCrunch - Executives At Disrupt Say The Future Of Healthcare Depends On Testing, Sensing, And Communication|
StartX is an educational non-profit that helps...